rs3077 — HLA-DPA1 HLA-DPA1 3′ UTR variant

Regulatory variant in the 3′ UTR of HLA-DPA1 that controls surface expression of HLA-DP antigen-presenting molecules; G allele reduces HLA-DPA1 mRNA expression and increases susceptibility to chronic hepatitis B infection while impairing HBV vaccine antibody response

See your personal result for HLA-DPA1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

HLA-DPA1 rs3077 — Your Immune System's Gatekeeper Against Hepatitis B

The HLA-DPA1 gene11 HLA-DPA1 gene
Human Leukocyte Antigen class II, DP Alpha 1 — encodes the alpha chain of the HLA-DP heterodimer, a surface receptor on antigen-presenting cells that displays peptide fragments to CD4+ T helper cells, initiating adaptive immune responses against pathogens sits at the centre of how your immune system recognises and clears hepatitis B virus (HBV). The rs3077 variant sits in the 3′ untranslated region of this gene — not altering the protein itself, but controlling how much of it gets made. The G allele at this position (equivalent to the C allele on the coding strand in many papers, because HLA-DPA1 is transcribed from the minus strand) silences HLA-DPA1 production in the liver, leaving the immune system less equipped to present HBV antigens and mount a clearing T-cell response.

The Mechanism

HLA-DP molecules are class II major histocompatibility complex22 major histocompatibility complex
MHC — the genomic region on chromosome 6p21 encoding cell-surface proteins that present peptide antigens to immune cells; essential for self/non-self discrimination and adaptive immunity proteins expressed on antigen-presenting cells — dendritic cells, B cells, macrophages, and Kupffer cells in the liver. They display short viral peptides to CD4+ T helper cells, which in turn coordinate antibody production by B cells and activation of CD8+ cytotoxic T cells that kill virus-infected hepatocytes. The rs3077 variant is the single strongest expression quantitative trait locus33 expression quantitative trait locus
eQTL — a genetic variant that controls the quantity of mRNA produced from a nearby gene; the rs3077 signal for HLA-DPA1 mRNA reached p=10⁻⁴⁸ in a genome-wide scan of liver tissue for HLA-DPA1 mRNA in human liver. Carrying the G allele means liver cells produce less HLA-DPA1 protein — meaning fewer HBV peptides are displayed, CD4+ T-cell help is blunted, and the virus is more likely to establish chronic infection rather than being cleared.

The Evidence

The association between rs3077 and hepatitis B chronicity is one of the most consistently replicated genetic findings in HBV research. A landmark study by An et al. 2011 in 1,742 Han Chinese44 An et al. 2011 in 1,742 Han Chinese
A common HLA-DPA1 variant is a major determinant of hepatitis B virus clearance established that the A allele (protective) was associated with a more than doubled likelihood of HBV clearance (OR 2.41, p<0.001) and a 38% reduced risk of chronic infection (OR 0.62, p=0.001). A subsequent meta-analysis of eight studies by Zhang et al. 201355 meta-analysis of eight studies by Zhang et al. 2013
Association of the rs3077 and rs9277535 polymorphisms with HBV infection and spontaneous clearance; pooled analysis of Asian cohorts confirmed an additive dose-response: each copy of the protective A allele further reduces the odds of chronic HBV, with AA homozygotes showing an OR of 0.35 (65% risk reduction) relative to GG homozygotes.

The same signal shapes hepatitis B vaccine response66 hepatitis B vaccine response
Standard HBV vaccination induces protective anti-HBs antibody titres ≥10 mIU/mL in >90% of recipients; the G allele at rs3077 is associated with impaired antibody production, making carriers more likely to be non-responders. A Japanese study of 278 healthcare workers found rs3077 was strongly associated with vaccine antibody response (OR 0.32, p=0.010) — GG carriers were disproportionately likely to fail to mount protective anti-HBs titres after standard vaccination. The finding replicated in Caucasian cohorts: Vermehren et al. identified a striking OR of 5.1 (CI 1.9–13.7) for HBV infection risk in European G-allele carriers, confirming the association extends beyond Asian populations.

The G allele frequency varies dramatically by ancestry: only ~17% in Europeans, ~30% in South Asians and Latinos, ~49% in Africans, and ~65% in East Asians — mirroring the global pattern of HBV endemicity and likely reflecting differential historical selection pressure from the virus.

Practical Actions

The clinical relevance of this variant depends on HBV exposure and vaccination status. For unvaccinated GG carriers, routine serology and consideration of enhanced vaccination protocols are the primary actions. For AG carriers, standard vaccination monitoring is appropriate. For those already vaccinated, checking post-vaccination anti-HBs titres is informative given the association with non-response. For those already chronically infected, the A allele at rs3077 predicts better HBsAg seroclearance during antiviral therapy — an important consideration for treatment planning with nucleot(s)ide analogues.

Interactions

The rs3077 signal is part of a broader HLA-DP haplotype. Its partner variant [rs9277535 | HLA-DPB1 3′ UTR — the beta-chain counterpart; commonly studied together with rs3077 as a two-SNP HLA-DP haplotype that additively predicts HBV outcomes], located in HLA-DPB1 (the beta chain gene adjacent to HLA-DPA1), independently tags HBV clearance and vaccine response. The CA haplotype (rs3077 A + rs9277535 A on the coding strand — i.e., plus-strand A at rs3077 + plus-strand A at rs9277535) is more strongly protective than either SNP alone (OR 0.57, CI 0.36–0.92 in the Indonesian replication study). This compound haplotype effect makes a strong case for profiling both variants together when assessing HBV susceptibility.

Genotype Interpretations

What each possible genotype means for this variant.

AA HLA-DP High Expresser Normal

Protective HLA-DPA1 genotype — strong HBV antigen presentation

The AA genotype at rs3077 is associated with higher HLA-DPA1 mRNA expression in liver tissue (the SNP with the strongest genome-wide eQTL signal for this gene, p=10⁻⁴⁸). Higher HLA-DPA1 expression means more HLA-DP heterodimers on the surface of liver antigen-presenting cells — more viral peptides displayed, and stronger CD4+ T-cell activation. In meta-analysis, AA homozygotes have a 65% reduced odds of developing chronic HBV infection compared to GG homozygotes (OR 0.35, Zhang et al. 2013). Standard hepatitis B vaccination typically achieves protective anti-HBs titres ≥10 mIU/mL in this genotype group at the expected rate.

AG HLA-DP Intermediate Expresser Intermediate

One G allele — moderately reduced HLA-DPA1 expression

The additive inheritance pattern at rs3077 means one G allele produces a proportionate reduction in HLA-DPA1 expression and an intermediate HBV susceptibility phenotype. The meta-analysis by Zhang et al. (2013) found AG vs GG OR=0.522 (CI 0.485–0.561) — meaning AG carriers are protected relative to GG, but less so than AA individuals. For vaccine response, the Japanese study by Okada et al. (2017) demonstrated that HLA-DP genotype predicts anti-HBs titres in an allele-dependent manner. Post-vaccination titre checking is advisable to confirm seroprotection, especially for healthcare workers or others with ongoing HBV exposure risk.

GG HLA-DP Low Expresser High Risk

Two G alleles — lowest HLA-DPA1 expression, highest HBV susceptibility

The GG genotype produces the strongest suppression of HLA-DPA1 mRNA expression — the G allele is the rs3077 eQTL risk allele with genome-wide significance (p=10⁻⁴⁸) for reduced HLA-DPA1 transcription in liver. Lower surface HLA-DP expression means fewer HBV peptides displayed to CD4+ T cells, blunted helper T-cell activation, impaired B-cell antibody production against HBV surface antigen, and reduced CD8+ cytotoxic T-cell killing of infected hepatocytes — a broad immunological disadvantage for clearing the virus.

If already chronically infected, rs3077 AA/AG genotype predicts better HBsAg seroclearance during nucleot(s)ide analogue therapy (Hosaka et al. 2015: p=0.003–0.004). GG carriers who are chronically infected may respond less robustly to antiviral therapy and benefit from close virological monitoring and discussion of treatment goals with a hepatologist. The companion variant rs9277535 (HLA-DPB1) should also be profiled — the combined CA haplotype (AA at both loci) provides stronger clearance prediction than either alone.